Low-dose IL-2 for in vivo expansion of CD4+ and CD8+ regulatory T cells in nonhuman primates

American Journal of Transplantation

Volumn 12, Issue 9, 2012, Pages 2532-2537

  Aoyama, A ^a   Klarin, D ^a   Yamada, Y ^a   Boskovic, S ^a   Nadazdin, O ^a   Kawai, K ^a   Schoenfeld, D ^a   Madsen, J C ^a   Cosimi, A B ^a   Benichou, G ^a   Kawai, T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Immunotherapy; interleukin 2; nonhuman primates; T regulatory cells

Indexed keywords

ALDELEUKIN; CD45RA ANTIGEN; RECOMBINANT INTERLEUKIN 2; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAPILLARY LEAK SYNDROME; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL PROLIFERATION; CELL TRANSPLANTATION; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; IMMUNOTHERAPY; IN VITRO STUDY; LOW DRUG DOSE; MALE; MEMORY T LYMPHOCYTE; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DOSE-RESPONSE RELATIONSHIP, DRUG; INTERLEUKIN-2; MACACA FASCICULARIS; MALE; T-LYMPHOCYTES, REGULATORY;

EID: 84865580488     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2012.04133.x     Document Type: Article

References (19)

1. +) regulatory T cells in human autoimmune diseases. Nat Rev Immunol 2010; 10: 849-859.
2. + T cell pool and tumor trafficking in patients with ovarian carcinoma. Cancer Res 2007; 67: 7487-7494. (Pubitemid 47206578)
3. + cells in renal allografts during acute rejection. Am J Transplant 2007; 7: 914-922. (Pubitemid 46481190)
4. + T-regulatory cells: Toward therapy for human diseases. Immunol Rev 2008; 223: 391-421. (Pubitemid 351986179)
5. Hippen KL, Merkel SC, Schirm DK, et al,. Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity. Sci Transl Med; 3 (83): 83ra41.
6. Nelson BH,. IL-2, regulatory T cells, and tolerance. J Immunol 2004; 172: 3983-3988. (Pubitemid 38375208)
7. Abrams D, Levy Y, Losso MH, et al,. Interleukin-2 therapy in patients with HIV infection. N Engl J Med 2009; 361: 1548-1559.
8. Shah MH, Freud AG, Benson DM, Jr,., et al. A phase I study of ultra low dose interleukin-2 and stem cell factor in patients with HIV infection or HIV and cancer. Clin Cancer Res 2006; 12: 3993-3996. (Pubitemid 44078085)
9. + regulatory T cell populations in interleukin-2-treated HIV patients. Proc Natl Acad Sci U S A; 107: 10632-10637.
10. + regulatory T cells. Nat Med 2005; 11: 1238-1243. (Pubitemid 43093672)
11. Saadoun D, Rosenzwajg M, Joly F, et al,. Regulatory T cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med; 365: 2067-2077.
12. Koreth J, Matsuoka K, Kim HT, et al,. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med; 365: 2055-2066.
13. Kawai T, Cosimi AB, Colvin RB, et al,. Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation 1995; 59: 256-262.
14. + T cells expressing the FoxP3 transcription factor. Immunity 2009; 30: 899-911.
15. +) regulatory T cells. Eur J Immunol 2008; 38: 1643-1653.
16. Stallmach A, Wittig B, Giese T, et al,. Protection of trinitrobenzene sulfonic acid-induced colitis by an interleukin 2-IgG2b fusion protein in mice. Gastroenterology 1999; 117: 866-876. (Pubitemid 29468229)
17. Zeiser R, Negrin RS,. Interleukin-2 receptor downstream events in regulatory T cells: Implications for the choice of immunosuppressive drug therapy. Cell Cycle 2008; 7: 458-462. (Pubitemid 351366473)
18. + regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 2006; 108: 1571-1579. (Pubitemid 44316124)
19. Bhatia S, Tykodi SS, Thompson JA,. Treatment of metastatic melanoma: An overview. Oncology (Williston Park) 2009; 23: 488-496.